PMID: 9537214Apr 16, 1998Paper

Interferon alpha-2b and megestrol acetate in the treatment of advanced renal cell carcinoma: a phase II study

American Journal of Clinical Oncology
F A Collichio, K Pandya

Abstract

Interferon-alpha has been used to treat advanced renal cell carcinoma, and megestrol acetate has been shown to improve the quality of life of patients who have cancer. We combined interferon alpha-2b, 10 million IU/m2 subcutaneously 5 consecutive days per week, with megestrol acetate, 80 mg orally twice a day, in 15 patients who had advanced renal cell carcinoma. Only 6 (40%) had a prior nephrectomy, and most had disease in the lung and other sites. There were no complete or partial responders to this treatment, although stable disease was achieved in 5 (33%) patients. The treatment was excessively toxic, with 12 (86%) patients requiring dose modification or discontinuation of treatment due to fatigue. We conclude that interferon alpha-2b and megestrol acetate is an excessively toxic, inactive regimen, at least in a group of patients who have advanced disease with a poor prognosis.

References

Aug 1, 1978·The Journal of Urology·J B DekernionR B Smith
Mar 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A FiglinJ deKernion
Jul 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D H IlsonG J Bosl
Oct 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R A FiglinG P Sarna
Feb 1, 1987·Cancer·G SarnaJ de Kernion
Feb 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H B MussM S Mitchell
Nov 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R QuesadaJ U Gutterman
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L M MinasianS E Krown
Sep 19, 1996·The New England Journal of Medicine·R J MotzerD M Nanus
Jan 1, 1997·CA: a Cancer Journal for Clinicians·S L ParkerP A Wingo

❮ Previous
Next ❯

Citations

May 18, 1999·Current Opinion in Oncology·P A Godley, T E Stinchcombe
Sep 28, 2005·Expert Opinion on Investigational Drugs·Justin P Favaro, Daniel J George
Oct 21, 2005·Cancer Treatment Reviews·Beverly J Drucker

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Critical Reviews in Oncology/hematology
Robert J Amato
The Urologic Clinics of North America
Matthew I Milowsky, David M Nanus
Current Treatment Options in Oncology
Robert C FlaniganMaria M Picken
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Brian I RiniN J Vogelzang
© 2022 Meta ULC. All rights reserved